Tuesday | Wednesday | Thursday | Friday | Saturday
FRIDAY, DECEMBER 13, 2019
   
6:45 am - 5:15 pm Registration - Main Lobby
   
7:00 am - 8:45 am SPOTLIGHT SESSION 9: Detection and Treatment Response Assessment - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Karla Sepulveda, MD
Baylor College of Medicine
Houston, TX

Discussants: 

Detection
Haydee Ojeda-Fournier, MD
UC San Diego Health Breast Imaging Division
La Jolla, CA

Treatment response 
Susan Weinstein, MD
University of Pennsylvania
Philadelphia, PA
   
7:00 am - 8:45 am SPOTLIGHT SESSION 10: Toxicity, Tolerability & Cost - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Katherine Reeder-Hayes, MD
University of North Carolina
Chapel Hill, NC

Discussants:

Patient reported outcomes
Norah Lynn Henry, MD, PhD
University of Michigan Rogel Cancer Center
Ann Arbor, MI

Cost and value
Michael Hasset, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

SES, Symptoms and treatment discontinuation
Katherine Reeder-Hayes, MD
University of North Carolina
Chapel Hill, NC
   
7:00 am - 8:45 am

POSTER SESSION 4 & continental breakfast – Hall 1

 
  Detection/Diagnosis  
  Pathology - Circulating Tumor Cells
Axillary Nodes - Axillary Staging and Sentinel Nodes
Pathology - Biopsy Techniques
P4-01
P4-02
P4-03
  Tumor Cell and Molecular Biology  
 

Epigenetics

Genomics
Tumor Heteroeneity/Molecular Subclassification
Molecular Profiles
Oncogenes/Tumor Suppressor Genes
Genetics - Somatic Changes

P4-04
P4-05
P4-06
P4-07
P4-08
P4-09

  Prognostic and Predictive Factors  
  Biomarkers Predicting Treatment Sensitivity and Resistance - Predictive Biomarkers for Targeted Therapies
Prognostic and Predictive Factors - Other
P4-10

P4-11
  Treatment  
  Surgery and Radiotherapy - Radiotherapy
Surgery and Radiotherapy - Breast Conservation
Other
Research Resources - Clinical Trials Design and Management
Research Resources - Patient Resources
Types and Sites of Breast Cancer - Male Breast Cancer
P4-12
P4-13
P4-14
P4-15
P4-16
P4-17
8:45 am - 9:30 am

DEBATE - Hall 3

 

Mastectomy should not be offered to patients who are breast conservation candidates when modern radiotherapy is available
Chairman: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

Lawrence B. Marks, MD, FASTRO
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC

Alastair M. Thompson, ALCM, BSc(Hons) MBChB, MD, FRCSEd(Gen)
Baylor College of Medicine
Houston, TX

9:30 am - 11:30 am

GENERAL SESSION 5 - Hall 3
Moderator: Tari King MD
Dana-Farber Cancer Center
Boston, MA

9:30 am  GS5-00. Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials
  Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick M, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL. Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Brigham and Women's Hospital, Boston, MA; Stanford Prevention Research Center, Stanford, CA; University of Washington, Seattle, WA; Pitt Public Health, Pittsburgh, PA; Karmanos Cancer Institute, Detroit, MI; Stony Brook University, Stony Brook, NY; University of Tennessee Health Science Center, Memphis, TN; Albert Einstein Cancer Center, Bronx, NY; The Ohio State University, Columbus, OH; UF Health Internal Medicine, Gainesville, FL
9:45 am

GS5-01. Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis

  Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A, Lae M, Martin M, del Monte M, I-SPY 2 TRIAL Consortium, Boughey JC, Gould R, Wesseling J, Steenbruggen T, van Seijen M, Sonke G, Edge S, Sammut S, Provenzano E, Abraham J, Hall P, Graham A, Mackintosh L, Cameron D, Wang A, Sharma P, Cole K, Pusztai L, Kim M, van ‘t Veer L, Esserman L, Symmans WF. University of California, San Francisco, San Francisco, CA; Institut Curie, Paris, France; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; Netherlands Cancer Institute, Amsterdam, Netherlands; Netherlands Cancer Institute, ,, Amsterdam, Netherlands; Roswell Park Comprehensive Cancer Center, Buffalo, NY; University of Cambridge, Cambridge, United Kingdom; University of Edinburgh, Edinburgh, United Kingdom; University of Kansas, Kansas City, KS; Yale University, New Haven, CA; Yale University, New Haven, CT.
10:00 am

GS5-02. Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158 

  Radovich M, Jiang G, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R,  Cooper ME, Pavlick DC, Albacker L, Gregg J, Bales CL, Hancock BA, Cantor E, Shen F, Storniolo AV, Badve S, Ballinger T, Miller KD, Schneider BP. Indiana University Simon Cancer Center, Indianapolis, IN; Medical College of Wisconsin, Milwaukee, WI; University of Chicago, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; Georgetown University, Washington, DC; Memorial Healthcare System, Hollywood, FL; Winship Cancer Institute of Emory University, Atlanta, GA; Community Regional Cancer Care, Indianapolis, IN; University of Florida, Gainesville, FL; University of Miami, Miami, FL; Aurora Health Care, Milwaukee, WI; Erlanger Health System, Chattanooga, TN; Foundation Medicine, Inc., Cambridge, MA.
10:15 am

GS5-03. Diagnosing residual disease and pathologic complete response after neoadjuvantchemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy:results of a prospective multicenter trial

  Heil J, Pfob A, Sinn H, Rauch G, Bach P, Schaefgen B, Weber W, Kuemmel S, Reimer T,Hahn M, Thill M, Blohmer J, Golatta M, RESPONDER Investigators. Department of Gynecology, University Hospital Heidelberg, Heidelberg, Germany; Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology, Berlin, Germany; Department of Surgery, University Hospital Basel, Basel, Switzerland; Kliniken Essen Mitte (KEM), Breast Unit, Essen, Germany; Department of Gynecology, University Hospital Rostock, Rostock, Germany; Department of Gynecology, University Hospital Tuebingen, Tuebingen, Germany; Department of Gynecology, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany; Department of Gynecology, University Hospital Berlin, Berlin, Germany
10:30 am GS5-04. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis
  Tasoulis M, Lee H, Yang W, Pope R, Krishnamurthy S, Kim S, Cho N, Teoh V, Rauch GM,  Smith BD, Valero V, Han W, Royal Marsden Hospital MDT, MacNeill F,  Kuerer HM. The Royal Marsden NHS Foundation Trust, London, United Kingdom; Seoul National University Hospital, Seoul, Republic of Korea; The University of Texas MD Anderson Cancer Center, Houston, TX.
10:45 am

GS5-05. Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery

  Basik M, Cecchini RS, De Los Santos JF, Umphrey HR, Julian TB, Mamounas EP, White J, Lucas PC, Balanoff C, Tan AR, Weber JJ, Edmonson D, Brown-Glaberman U, Diego EJ, Teshome M, Matsen CB, Seaward SA, Wapnir IL, Wagner JL, Tjoe JA, Thompson AM, Wolmark N. NRG Oncology, Philadelphia, PA; Jewish General Hospital, Montreal, Quebec; University of Pittsburgh, Pittsburgh, PA, Grandview Cancer Center, Birmingham, AL; NEA Baptist Memorial Hospital, Jonesboro, AK; Allegheny Health Network Cancer Institute, Pittsburgh, PA; Orlando Health UF Cancer Center, Orlando, FL; Ohio State University Comprehensive Cancer Center, Columbus, OH; University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA; University of Kansas Cancer Center - MCA Rural MU NCORP, Kansas City, KS; Levine Cancer Institute, Atrium Health, Charlotte, NC; Advocate Aurora Health, Aurora Research Institute, Milwaukee, WI; Women & Infants Hospital/Brown University, Providence, RI; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Texas MD Anderson Cancer Center LAPS, Houston, TX;
University of Utah - Huntsman Cancer Institute LAPS, Salt Lake City, UT; Kaiser Permanente Oncology Clinical Trials, Vallejo, CA; Stanford Cancer Institute, Stanford, CA;
ALLIANCE, and The University of Kansas Cancer Center, Kansas City, KS; ECOG-ACRIN, Philadelphia, PA; SWOG, and Baylor College of Medicine, Houston, TX.
11:00 am  GS5-06. Toward omitting breast surgery in patients with a pathologic complete response after neoadjuvant  systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment)
  Vrancken Peeters MTFD, van Loevezijn A, van der Noordaa MEM, van Duijnhoven FH,Loo CE, van Werkhoven E, van de Vijver KK, Wiersma T, Winter-Warnars HAO, SonkeGS. 
11:15 am

GS5-07. Discussant
Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

   
10:45 am - 5:00 pm EXHIBITS - Hall 2
   
11:30 am - 12:00 pm

2019 AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, supported by the Breast Cancer Research Foundation - Hall 3

  Novel Non-canonical Functions of EZH2 in Triple Negative Breast Cancer
Celina Kleer, MD
University of Michigan Medical School
Ann Arbor, MI
   
12:00 pm - 1:00 pm BREAK
   
12:00 pm - 1:00 pm  NETWORKING WITH THE EXPERTS - Hall 2 
 

Networking with the Experts will be offered as a “can’t miss” opportunity for young and established investigators alike at the 2019 San Antonio Breast Cancer Symposium. The event will have several groups focusing on rapidly advancing areas of research hosted by luminaries in the respective fields. There will be no formal program, but participation in one of the groups will be a fun opportunity to socialize and network with colleagues and potential collaborators working in your area, as well as some of the most respected investigators in the breast cancer research community. This year will feature the researchers in following groups:     

Clinical Trials Design in the Era of Precision Medicine 
Lisa Carey, MD, MSc
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC 

Lajos Pusztai, MD, PhD
Yale University School of Medicine
New Haven, CT 

Ian Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA   

Patient Reported Outcomes and Survivorship
Jennifer Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA
 
Katherine Reeder-Hayes, MD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Kathryn Ruddy, MD, MPH
Mayo Clinic Cancer Center
Rochester, MN   

Liquid Biopsies and Genomics
Ben Park, MD, MPH
Vanderbilt-Ingram Cancer Center
Nashville, TN 

Nicholas C. Turner, PhD
Royal Marsden Hospital Institute of Cancer Research
London, UNITED KINGDOM

Minetta Liu, MD
Mayo Clinic College of Medicine
Rochester, MN

   
1:00 pm - 2:00 pm

CASE DISCUSSION 2 - Stars at Night Ballroom 1&2 - 3rd Level

  Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists: 

Antonio C. Wolff, MD
Johns Hopkins Medicine
Baltimore, MD

Mylin A. Torres, MD
Emory University 
Atlanta, GA

Minetta  Liu, MD
Mayo Clinic
Rochester, MN

W. Fraser Symmans, MD
UT MD Anderson Cancer Center
Houston, TX

Ingrid M. Meszoely, MD
Vanderbilt University Medical Center
Nashville, TN

Jane Perlmutter, PhD
Gemini Group
Ann Arbor, MI
   
1:00 pm - 2:00 pm TRANSLATIONAL SCIENCE FORUM 2 - Stars at Night Ballroom 3&4 - 3rd Level
 

The Communal Road to Metastasis: CTC Clusters
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Lester & Sue Smith Breast Center
Houston, TX

CTC clusters, cancer stemness, and new treatment strategies
Huiping Liu, MD, PhD
Northwestern University
Chicago, IL

Biology, vulnerabilities and clinical implications of CTC clusters
Nicola Aceto, PhD
University of Basel
Basel, SWITZERLAND

2:15 pm - 3:15 pm

MINI-SYMPOSIUM 2 - Hall 3

 

Targeting the Cell Cycle Kinase CDK 4/6 and Beyond
Moderator: Angela DeMichele, MD, MSCE
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Mechanisms of resistance to CDK4/6 inhibitors and new therapeutic approaches
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Targeting the cell cycle - Beyond CDK4/6 inhibition
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

3:15 pm - 5:00 pm

GENERAL SESSION 6 - Hall 3
Moderator: Naoto Ueno, MD, PhD
MD Anderson Cancer Center
Houston, TX

3:15 pm GS6-01. Oral Paclitaxel with Encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a phase III clinical study in metastatic breast cancer
  Umanzor G, Rugo H, Cutler DL, Barrios FJ, Vasallo RH, Chivalan MA, Bejarano S, Ramirez JR, Fein L, Kramer D, Kowalyszyn RD, Goldfinch J, Wang H, Moore T, Kwan RMF. Athenex, Cranford, NJ; DEMEDICA, San Pedro Sula, Honduras; Insitituto de Cancerologia INCAN, Guatemala City, Guatemala; Clinical Research RD, Santo Domingo, Dominican Republic; CELAN Clinica Medica, Guatemala City, Guatemala; Excel Medica, San Pedro Sula, Honduras; CRESEM, Quetzaltenango, Guatemala; Instituto de Oncologia de Rosario, Rosario, Argentina; Centro de Investigaciones Clinica, Clinica Viedma, Viedma, Argentina; Athenex, Buffalo, NY.
3:30 pm

GS6-02. Apobec and BRCA mutation signatures are mutually exclusive in breast cancer


Harris RS, Smid M, Wilting S, Roelofs P, Serebrenik A, Law E, Jarvis M, Span P,Martens JWM. University of Minnesota, Minneapolis, MN; ErasmusMC, Rotterdam, Netherlands.
3:45 pm  GS6-03 Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment ingermline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer:Results from the INFORM trial (TBCRC 031)
  Tung N, Arun B, Hofstatter E, Hacker MR, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Krop IE, Winer EP, Schnitt SJ, Garber JE. Beth Israel Deaconess Medical Center, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Yale Cancer Center, New Haven, CT; Rutgers Cancer Institute of New Jersey, Rutgers, NJ; Massachusetts General Hospital, Boston, MA; University of Colorado Cancer Center, Denver, CO; Women and Infants Hospital, Providence, RI; Lombardi Comprehensive Cancer Center, Washington, DC; Johns Hopkins Kimmel Cancer Center, Baltimore, MD; Duke Cancer Institute, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
4:00 pm

GS6-04. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity

  Hanker AB, Sekar Jayanthan H, Ye D, Lin C, Akamatsu H, Sheehan JH, Koch JP, Sudhan DR, Red Brewer M, Servetto A, He J, Miller VA, Lalani AS, Meiler J, Arteaga CL. UT Southwestern Medical Center, Dallas, TX; Vanderbilt University, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA.
4:15 pm

GS6-05. A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment

  Cohen O, Abravanel D, Slyper M, Klughammer J, Jane-Valbuena J, Helvie K, Dellostritto L, Frangieh A, Vigneau S, Wu J, Mayorga A, Waldman J, Nguyen L, Dionne D, Ashenberg O, Hofree M, Cuoco M, Rodman C, Winer EP, Lin N, Johnson B, Rotem A, Rozenblatt-Rosen O, Regev A, Wagle N. Dana-Farber Cancer Institute, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA.
4:30 pm

GS6-06. A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer

  Lee K, Guerrero-Zotano A, Hanker A, Servetto A, Sudhan D, Formisano L, Jansen V, González-Ericsson P, Sanders M, Stricker T, Cantley L, Arteaga C. UT Southwestern Medical Center, Dallas, TX; Vanderbilt University Medical Center, Nashville, TN; Weill Cornell Medicine College, New York, NY.
4:45 pm

GS6-07. Discussant
Adrian V. Lee, PhD
University of Pittsburgh
Hillman Cancer Center
Pittsburgh, PA

   
5:00 pm - 7:00 pm

POSTER SESSION 5 & reception - Hall 1

 

Detection/Diagnosis

 

Pathology - Circulating Biomarkers and ctDNA
Pathology - Diagnostic Pathology

P5-01
P5-02

 

Tumor Cell and Molecular Biology

                       

Genetics - Germline Changes
Immunology and Preclinical Immunotherapy
New Drugs and Mechanisms

P5-03
P5-04
P5-05

  Prognostic and Predictive Factors  
 

Prognostic Factors - Clinical Testing and Validation

P5-06

  Epidemiology, Risk, and Prevention  
  Risk Factors and Modeling
Other
P5-07
P5-08
  Psychosocial, QOL, and Educational Aspects  
  Quality of Life Issues - Palliation and Pain Management
Quality of Life Issues - Psychosocial Aspects 
P5-09
P5-10
  Treatment  
 

Advanced Disease Treatment - Advanced Endocrine Therapy
Adjuvant Endocrine Therapy
Therapeutic Strategies - Neoadjuvant Endocrine Therapy
Therapeutic Strategies - Toxicities - Management

P5-11
P5-12
P5-13
P5-14

  Ongoing Trials  
  Axillary Nodes
Imaging
Screening
Biopsy
Breast-Conserving Treatment
Surgery
Ultrasonic Ablation
Radiation Therapy
DCIS
Brain Metastases
Male Breast Cancer
Supportive Care
Cost-Effectiveness
Patient Management
Risk Reduction
Quality of Life
Response Predictions
Circulating Tumor Cells
Trials - Patient-Reported Outcomes
OT3-01
OT3-02
OT3-03
OT3-04
OT3-05
OT3-06
OT3-07
OT3-08
OT3-09
OT3-10
OT3-11
OT3-12
OT3-13
OT3-14
OT3-15
OT3-16
OT3-17
OT3-18
OT3-19
6:00 pm - 7:30 pm SPECIAL SESSION
Stars at Night Ballroom 3&4 - 3rd Level
View from the Trenches: What Will You Do On Monday Morning?
Moderator: Ruth O'Regan, MD
University of Wisconsin
Carbone Cancer Center
Madison, WI

Panel Members:

Nadia Harbeck, MD, PhD
Ludwig Maximilian University of Munich
Munich, GERMANY

E. Shelley Hwang, MD, MPH
Duke University
Durham, NC

Debra A. Patt, MD, MPH
Texas Oncology
Austin, TX

Bárbara Segarra-Vázquez, DHSc
University of Puerto Rico
San Juan, PR

Joseph Sparano, MD
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY

7:30 pm OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter, Grand Ballroom G-M
Data + Perspectives: Clinical Investigators Explore the Current and Future Management of HER2- Positive Breast Cancer

For further information and to register for this event, visit
http://www.researchtopractice.com/Meetings/SA2019
 
Tuesday | Wednesday | Thursday | Friday | Saturday
 
In collaboration with  Astro     and     SSO